PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer- United Kingdom

doi 10.1038/sj.bjc.6604009

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

PTEN Status in Advanced Colorectal Cancer Treated With Cetuximab

British Journal of Cancer
Cancer ResearchOncology
2009English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results From CALGB 80203 (Alliance)

Clinical Cancer Research
Cancer ResearchOncology
2014English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

Loss of Smad4 Expression Predicts Liver Metastasis in Human Colorectal Cancer

Oncology Reports
MedicineCancer ResearchOncology
2007English

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

Predictive Value of TLR7 Polymorphism for Cetuximab-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

International Journal of Cancer
Cancer ResearchOncology
2017English

Efficacy of Continued Cetuximab for Unresectable Metastatic Colorectal Cancer After Disease Progression During First-Line Cetuximab-Based Chemotherapy: A Retrospective Cohort Study

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy